Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) EPS (Basic) (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed EPS (Basic) for 7 consecutive years, with -$0.17 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) rose 39.29% to -$0.17 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.87 through Dec 2025, up 34.59% year-over-year, with the annual reading at -$0.87 for FY2025, 34.09% up from the prior year.
  • EPS (Basic) hit -$0.17 in Q4 2025 for Allogene Therapeutics, up from -$0.19 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.01 in Q4 2021 to a low of -$0.69 in Q1 2023.
  • Historically, EPS (Basic) has averaged -$0.4 across 5 years, with a median of -$0.38 in 2023.
  • Biggest five-year swings in EPS (Basic): soared 100.93% in 2021 and later tumbled 6900.0% in 2022.
  • Year by year, EPS (Basic) stood at $0.01 in 2021, then crashed by 6900.0% to -$0.68 in 2022, then increased by 25.0% to -$0.51 in 2023, then skyrocketed by 45.1% to -$0.28 in 2024, then soared by 39.29% to -$0.17 in 2025.
  • Business Quant data shows EPS (Basic) for ALLO at -$0.17 in Q4 2025, -$0.19 in Q3 2025, and -$0.23 in Q2 2025.